Podcast | Late Breaking Clinical Trial Data from AHA 2025 on Approved and Emerging Lipid Lowering Therapies: Highlights Selected by the Experts

Course Title for Certificate
Name*

First NameLast Name
Email*
example@example.com
MDRN/NPPharmDPAProfessorIndustryOther
If PharmD, DOB

MonthDayYear
Date
If PharmD, NABP ID#:
How many years have you been in practice?
a. Up to 40%b. Up to 53%c. Up to 72%d. Up to 90%
a. 20b. 35c. 12d. 4
a. Patient with prior MI and PCI to the LADb. Patient with PADc. Patient with prior stroked. Patient with prediabetes
a. 35%b. 40%c. 57%d. 65%
Less than 55-1516-2526-3536-4546 or moreN/A

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Analyze and contextualize newer clinical data for therapies to lower LDL-C and Lp(a) levels as presented at AHA 2025
Discuss how to utilize combinations of lipid- lowering therapies to improve long term outcomes for dyslipidemia patients with (or at risk for) atherosclerosis

Please provide us with feedback regarding your experience at the activity:

YesNo
If no, please explain:
YesNoN/A
I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Attestation:

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of Continuing Pharmacy Education Credit (UAN # JA4008190 0000-25-036-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.
Date

MonthDayYear
Date
Credits
Should be Empty: